SecurityKMR / Kinder Morgan, Inc. (49455U100)
President and CEOKEAN STEVEN J
IndustryNatural Gas Transmission
Institutional Owners0
Common Shares Outstanding2,206,071,454 shares (as of 2018-03-31)
Related 28336LBB4 / El Paso 6.7% Senior Notes 2/15/27
28336LBM0 / El Paso 6.875% Senior Notes 6/15/14
KMRFZ / Kinder Morgan Cum Pfd Ser A 144A
49455WAD8 / Kinder Morgan Finance Corp Ulc Guaranteed Notes 5.7% 01/05/16
49455WAF3 / Kinder Morgan Finance Corp Ulc Guaranteed Notes 6.4% 01/05/36
KMI / Kinder Morgan, Inc.
KMI.PRA / Kinder Morgan, Inc. 9.75% Dep Shares Series A Mandatory Convertible Preferred Stock
494553AC4 / Kinder Morgan Inc Senior Notes 5.15% 03/01/15
KMI.WS / Kinder Morgan, Inc. Warrants
482620AW1 / Kn Energy Inc Sr Db 7.25% 03/01/28
482620AX9 / Kn Energy Inc Sr Db 7.45% 03/01/98
CVB / Lehman ABS Corp Bkd Trust Certs 2002-06, 7.75% Kinder Morgan Debentures

Institutional Stock Ownership and Shareholders

KMR / Kinder Morgan, Inc. Institutional Ownership

Kinder Morgan, Inc. (NYSE:KMR) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include .
Kinder Morgan, Inc. (NYSE:KMR) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href=""><img src="" alt="KMR / Kinder Morgan, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Prev Value
Current Value

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

11h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

Top Analyst Upgrades and Downgrades: BlackRock, Chevron, Disney, Intel, Kinder Morgan, Zillow and More

4h 247wallst
The futures traded lower again Monday morning as we look to see some follow-through selling in the wake of the announcement on the tariffs starting on some overseas products in early July. Investors should be heartened by the outstanding economic news that continues to pour in, and with only two weeks left in the second quarter, it’s a solid bet that earnings will be very positive. (115-1)

John Horgan wants your dad jokes — but also your personal information

These are obviously bad jokes. But they're also bad jokes told by John Horgan, premier of British Columbia, in scripted videos released to the public. (6-0)

John Horgan wants your dad jokes — but also your personal information

These are obviously bad jokes. But they're also bad jokes told by John Horgan, premier of British Columbia, in scripted videos released to the public. (6-0)

Weighing The Week Ahead: What Is Working And Will It Persist?

2018-06-17 seekingalpha
The economic calendar is modest. Volatility is lower even with plenty of news. The summer doldrums have arrived! (191-0)

Brookfield CEO Says He May Consider Trans Mountain Investment

2018-06-15 rigzone
(Bloomberg) -- Brookfield Asset Management Inc., Canada’s largest alternative asset manager, may consider investing in the Trans Mountain pipeline -- if it would produce an attractive return. (35-0)

CUSIP: 49455U100